ScientiaCME From autoimmunity to action: improving recognition and advancing care in lupus nephritis
In this online, self-learning activity:
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), affecting over 40% of patients with lupus. It is a major contributor to morbidity, healthcare utilization, and progression to end-stage renal disease (ESRD). The prevalence of LN has increased significantly over time, from 16.8 per 100,000 in 1985 to 21.2 per 100,000 more recently. The mortality rate associated with LN remains high with a standardized mortality ratio of 6.33 compared to the general population. Despite increased advances in treatments, long-term survival rates have not improved significantly over the past four decades. The 10-year survival rate is around 70%, while the incidence of progression in ESRD in LN patients affects up to 13% of patients over time.
Cost: Free
View Offer chevron_rightDetails
In this online, self-learning activity:
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), affecting over 40% of patients with lupus. It is a major contributor to morbidity, healthcare utilization, and progression to end-stage renal disease (ESRD). The prevalence of LN has increased significantly over time, from 16.8 per 100,000 in 1985 to 21.2 per 100,000 more recently. The mortality rate associated with LN remains high with a standardized mortality ratio of 6.33 compared to the general population. Despite increased advances in treatments, long-term survival rates have not improved significantly over the past four decades. The 10-year survival rate is around 70%, while the incidence of progression in ESRD in LN patients affects up to 13% of patients over time.
Learning Objectives
By the end of the session the participant will be able to:
- Summarize challenges related to the healthcare burden, identification, and management of lupus nephritis.
- Identify the present and emerging pharmacotherapeutic treatment options for the management of lupus nephritis.
- Formulate a treatment plan for a patient with lupus nephritis.
Target Audience
HCPs including but not limited to: rheumatologists and nephrologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and other HCPs who have an interest in or commonly encounter patients with lupus nephritis.
Additional credit info
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-26-008-H01-P. This is an Application (A)-type activity.

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™, and the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ to meet the continuing education renewal requirements of nursing re-certification for APRNs and RN specialty. Some state nursing boards accept AMA PRA Category 1 Credit(s)™ for re-licensure requirements, some do not. Check your state board of nursing’s CE requirements before applying credit from this course to your re-licensure.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.